Supporting our client with a successful submission to NICE’s Highly Specialised Technology (HST) programme

Helping a growing US biopharma company navigate product reimbursement across Europe

Supporting our client through the UK Promising Innovative Medicine (PIM) designation as part of the Early Access to Medicines Scheme (EAMS)

Securing a price rise for an existing medicine

Removing our client’s high-cost medicine from the NHS tariff

MAP’s work on improving access to orphan medicines has helped to strengthen the case for change and encourage greater external pressure

Securing a change in a proposed NHS England prescribing restriction for acute pain medication in primary care

Putting our global client and their key issue on the UK map